Veracyte Announces First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- US stock futures gain ahead of July inflation data
- Oil rises after attacks on ships in Hormuz, Bab el-Mandeb
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Veracyte (VCYT) Tops Q1 EPS by 3c, Reiterates FY Outlook
May 14, 2015 4:28 PM EDTVeracyte (NASDAQ: VCYT) reported Q1 EPS of ($0.34), $0.03 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $11.2 million versus the consensus estimate of $10.83 million.
2015 Financial Outlook
Veracyte reiterates its 2015 annual revenue guidance of $48 million to $53 million, as well... More
